AstraZeneca’s Imfinzi plus chemotherapy doubled overall survival rate for patients with advanced biliary tract cancer
Longest survival follow-up ever reported for immunotherapy treatment in this setting
Longest survival follow-up ever reported for immunotherapy treatment in this setting
The Gold Medal distinction places the company in the top 5% of all organizations assessed within EcoVadis's rigorous framework globally
CHL is strengthening its play in the fast-growing beauty and personal care sector
Global Phase-3 study initiation expected in the second half of 2024
KRKA holds 51% and Laurus Labs holds 49% shareholding
The offer price corresponds to a premium of 142% on the volume-weighted average price during the last three months
Ajovy confirms efficacy in new Phase 3 data significantly reducing the number of migraine days per month
This facility manufactures APIs & formulations of oncology and non-oncology products.
The inspection was conducted from April 8 to April 12, 2024 and concluded with no observations
Subscribe To Our Newsletter & Stay Updated